This is an investment opportunity you cannot afford to miss!
Seegnal
A groundbreaking company that has developed intelligent SAAS software enabling physicians and pharmacists to personalize medication for patients, is in the final stages before its anticipated IPO on the Canadian stock exchange
Because we strongly believe in the company, we are offering two attractive investment tracks
Starting from NIS 130,000
Would you like to learn more about the investment options?
Leave Your Details Now!
One in four people will suffer severe side effects (including death) in their lifetime due to incorrect medications
Every year in the United States, $40 billion is spent treating problems caused by administering incorrect medications to patients
The phenomenon of administering incorrect medications is currently considered the fourth leading cause of death worldwide!
The company has developed a system that helps physicians and pharmacists provide personalized medication treatment to patients, alerts them to medications that contradict other medications or the patient’s medical data, and even recommends alternative medication treatments, thereby significantly reducing and even preventing this phenomenon
Seegnal’s system is operational and already in use by 10,000 physicians, scanning over one million medications per day
Seegnal is experiencing business momentum worldwide—this is your opportunity to participate in its success
» The system is already being implemented in the systems of Maccabi and Leumit health funds, and at Rambam and Ichilov hospitals
» Seegnal has signed a marketing, distribution, and maintenance agreement with NESS, which will represent it in the Ministry of Health tender for implementing the system in all government hospitals in Israel, and in selling it to additional health funds and hospitals in Israel.
» Seegnal’s intelligent system currently operates in two hospitals in Abu Dhabi.
» The company has completed the first phase of a pilot for matching medications to patients based on their DNA data. It is now preparing for the next phase, which will be conducted on 1,500 patients, funded by the UAE Ministry of Health. Following the success of the second phase, the system is planned to be implemented in all hospitals in the Emirates.
» Although the pilot has not yet concluded, the Pure Health hospital network, operating in the UAE, has chosen to implement Seegnal’s intelligent system, including DNA-based matching, in the network’s 20 hospitals. The contract, expected to be signed upon the conclusion of the war in Gaza, is projected to generate revenues exceeding $40 million for the company over a ten-year period.
» Seegnal’s system is also generating enthusiasm in Europe, and a pilot of the system has recently been signed at a hospital in Poland.
Alongside all these impressive achievements, Seegnal has signed a binding agreement with the Canadian public company CAPITAL REEM, which means it is one and a half steps away from its IPO on the Canadian stock exchange!
Fill in your details and receive additional information about the opportunity to invest in Seegnal—just before it goes public
Do not miss this opportunity, leave your details now and discover the attractive investment channels!